Roche Acquires POC MDx Firm Iquum | GenomeWeb

NEW YORK (GenomeWeb News) — Roche said today that it has acquired Iquum, a privately held company developing point-of-care molecular diagnostics.

Under the terms of the agreement, Roche will pay Iquum shareholders $275 million upfront and up to $175 million in contingent product-related milestones. Once the transaction is complete, pending customary closing conditions, Marlborough, Mass.-based Iquum will be integrated into Roche Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.